BeiGene Highlights Innovative Hematology Portfolio Across B-cell Malignancies at ASH 2024
Reading Time: 11 minutes San Mateo, Calif., United States: Five-year results of Phase 3 SEQUOIA study demonstrate durable benefits of BRUKINSA in patients with CLL Two oral presentations showcase promising safety and efficacy data for BTK chimeric degradation activation compound (CDAC), BGB-16673 Oral presentation highlights
Diageo India Releases 2024 ESG Reporting Index Highlights Achievements Across Its ‘Spirit of Progress’ Goals
Reading Time: 6 minutes Diageo India (United Spirits Ltd.), among the country’s leading alco-bev companies, launched its third annual ESG Reporting Index 2024 today, highlighting continued progress in the company’s ‘Spirit of Progress’ ESG action plan. The Reporting Index shares impacts across three key objectives outlined in Diageo’s Spirit
OCBC Forms Strategic Partnership With Ant International to Enhance the Efficiency of Cross-Border Fund Settlements Through Innovations in Tokenised Deposits
Reading Time: 3 minutes Singapore: OCBC and Ant International have formed a strategic partnership to enhance the efficiency and speed of cross-border fund settlements. In a Memorandum of Understanding (MoU) signed on 5 November 2024 by Melvyn Low, Head of Global Transaction Banking at OCBC,and
#24-379 Listing of Derivatives at NGM
Reading Time: < 1 minute Information about various derivatives that will be listed at NGM. For more details, see attached file. For further information concerning this NGM notice please contact NGM Listing department on listings@ngm.se. Nordic Growth Market NGM AB About NGM Nordic Growth Market
#24-380 Delisting of Derivatives from NGM
Reading Time: < 1 minute Information about certain derivatives that will be delisted from NGM. For further information concerning this NGM notice please contact NGM Listing department on listings@ngm.se. Nordic Growth Market NGM AB About NGM Nordic Growth Market NGM AB (NGM) is an authorized
BLA for pegzilarginase in the treatment of arginase 1 deficiency (ARG1-D) accepted for priority review by the U.S. FDA
Reading Time: 2 minutes Stockholm, November 5, 2024: Immedica announces today that the Biologics License Application (BLA) for pegzilarginase in the treatment of arginase 1 deficiency (ARG1-D) has been successfully validated and accepted for priority review by the U.S. Food and Drug Administration (FDA). Anders
Diamyd Medical and INNODIA partner for Type 1 Diabetes awareness and patient recruitment for the DIAGNODE-3 precision medicine trial
Reading Time: 3 minutes Diamyd Medical has entered a strategic partnership with INNODIA, an international non-profit organization dedicated to advancing research on disease modifying therapies for Type 1 Diabetes. The partnership will leverage INNODIA’s extensive EU-based clinical network with the aim to further amplify patient enrolment
SOFTSWISS Wins SBC Latinoamérica Award for Help Brazil Initiative
Reading Time: 2 minutes SOFTSWISS has won the Socially Responsible Initiative of the Year nomination at the SBC Awards Latinoamérica 2024 for its impactful ‘Help Brazil’ initiative. This recognition underscores the company’s support for Brazilian communities affected by severe flooding earlier this year and its dedication to
Noble Corporation plc Provides Guidance
Reading Time: < 1 minute SUGAR LAND, TEXAS, Nov. 5, 2024 /PRNewswire/ – Noble Corporation plc (“Noble”) (CSE: NOBLE, NYSE: NE) today provides guidance for the quarter ended December 31, 2024. In accordance with Danish legal and stock exchange requirements, Noble announced that for the quarter
THOMSON IMPROVES ENERGY EFFICIENCY OF MEDIUM-DUTY APPLICATIONS WITH NEW 48-VOLT ELECTRIC LINEAR ACTUATOR
Reading Time: 3 minutes Editorial Contact: Shreyasi Bhaumik – +44 (0) 203 409 5090Company Contact: Kevin Bastian – +1 630 694 3342 Please quote the following contact information when publishing:Tel.: 540.633.3549, Fax: 540.633.0294, www.thomsonlinear.com; Thomson@regalrexnord.com 11.05.2024, DOWNERS GROVE, IL – Thomson Industries, Inc., a